CANCER:

Non Small Cell Lung Cancer

Related cancers:

‹

Lung Adenocarcinoma (456)

Lung Non-Squamous Non-Small Cell Cancer (86)

Lung Non-Small Cell Squamous Cancer (83)

Lung Adenocarcinoma (456)

Lung Non-Squamous Non-Small Cell Cancer (86)

Lung Non-Small Cell Squamous Cancer (83)

›

No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval FDA - 3 days (NewA1)	pemetrexed Sensitive: A1 - Approval FDA - 3 days - (New A1)
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval FDA - 3 days (NewA1)	cisplatin + pemetrexed Sensitive: A1 - Approval FDA - 3 days - (New A1)
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A1 - Approval FDA - 3 days (NewA1)	pembrolizumab Sensitive: A1 - Approval FDA - 3 days - (New A1)
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: A1 - Approval N Engl J Med - 3 days (NewA1)	nivolumab Sensitive: A1 - Approval N Engl J Med - 3 days - (New B)
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval Chugai Press Release - 3 days (NewA1)	atezolizumab Sensitive: A1 - Approval Chugai Press Release - 3 days - (New A1)
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A1 - Approval Cancer Med - 3 days (NewA1)	alectinib Sensitive: A1 - Approval Cancer Med - 3 days - (New C3)
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	Angiogenesis inhibitor Sensitive: C3 – Early Trials Cancer Med - 5 days (NewC3)	Angiogenesis inhibitor Sensitive: C3 – Early Trials Cancer Med - 5 days - (New C3)
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A1 - Approval J Clin Oncol - 6 days (NewA1)	lorlatinib Sensitive: A1 - Approval J Clin Oncol - 6 days - (New B)
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	dostarlimab Sensitive: C2 – Inclusion Criteria Clin Lung Cancer - 6 days (NewC2)	dostarlimab Sensitive: C2 – Inclusion Criteria Clin Lung Cancer - 6 days - (New C3)
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials BMC Cancer - 6 days (NewC3)	EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials BMC Cancer - 6 days - (New C3)
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	sugemalimab Sensitive: A1 - Approval CStone Pharma Press Release - 1 week (NewA1)	sugemalimab Sensitive: A1 - Approval CStone Pharma Press Release - 1 week - (New B)
CD276 underexpression + EGFR mutation CD276 underexpression + EGFR mutation	Lung Adenocarcinoma LUAD	CD276 underexpression + EGFR mutation CD276 underexpression + EGFR mutation	Lung Adenocarcinoma LUAD	EGFR inhibitor Sensitive: C3 – Early Trials World J Surg Oncol - 1 week (NewC3)	EGFR inhibitor Sensitive: C3 – Early Trials World J Surg Oncol - 1 week - (New C3)
EML4-ALK fusion EML4-ALK fusion	Non Small Cell Lung Cancer NSCLC	EML4-ALK fusion EML4-ALK fusion	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: C3 – Early Trials Int J Cancer - 1 week (NewC3)	alectinib Sensitive: C3 – Early Trials Int J Cancer - 1 week - (New C3)
EGFR mutation + RET fusion EGFR mutation + RET fusion	Non Small Cell Lung Cancer NSCLC	EGFR mutation + RET fusion EGFR mutation + RET fusion	Non Small Cell Lung Cancer NSCLC	osimertinib + pralsetinib Sensitive: C3 – Early Trials JTO Clin Res Rep - 1 week (NewC3)	osimertinib + pralsetinib Sensitive: C3 – Early Trials JTO Clin Res Rep - 1 week - (New C3)
EML4-ALK fusion + TP53 mutation EML4-ALK fusion + TP53 mutation	Non Small Cell Lung Cancer NSCLC	EML4-ALK fusion + TP53 mutation EML4-ALK fusion + TP53 mutation	Non Small Cell Lung Cancer NSCLC	alectinib Resistant: C3 – Early Trials Int J Cancer - 1 week (NewC3)	alectinib Resistant: C3 – Early Trials Int J Cancer - 1 week - (New C3)
SLC12A2-ROS1 fusion SLC12A2-ROS1 fusion	Non Small Cell Lung Cancer NSCLC	SLC12A2-ROS1 fusion SLC12A2-ROS1 fusion	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: C4 – Case Studies SAGE Open Med Case Rep - 1 week (NewC4)	crizotinib Sensitive: C4 – Case Studies SAGE Open Med Case Rep - 1 week - (New C4)
EGFR V786M EGFR V786M	Lung Adenocarcinoma LUAD	EGFR V786M EGFR V786M	Lung Adenocarcinoma LUAD	EGFR inhibitor Sensitive: C4 – Case Studies Front Oncol - 1 week (NewC4)	EGFR inhibitor Sensitive: C4 – Case Studies Front Oncol - 1 week - (New C4)
LMO7-ALK rearrangement LMO7-ALK rearrangement	Lung Adenocarcinoma LUAD	LMO7-ALK rearrangement LMO7-ALK rearrangement	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C4 – Case Studies Front Oncol - 1 week (NewC4)	crizotinib Sensitive: C4 – Case Studies Front Oncol - 1 week - (New C4)
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A2 - Guideline Int J Clin Oncol - 2 weeks (NewA2)	pembrolizumab Sensitive: A2 - Guideline Int J Clin Oncol - 2 weeks - (New C3)
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: B - Late Trials Oncotarget - 2 weeks (NewB)	Immunotherapy Sensitive: B - Late Trials Oncotarget - 2 weeks - (New C3)
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab + RG6058 Sensitive: B - Late Trials Roche Press Release - 2 weeks (NewB)	atezolizumab + RG6058 Sensitive: B - Late Trials Roche Press Release - 2 weeks - (New B)
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	TPX-0005 Sensitive: B - Late Trials Turning Point Therapeutics Press Release - 2 weeks (NewB)	TPX-0005 Sensitive: B - Late Trials Turning Point Therapeutics Press Release - 2 weeks - (New B)
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval Precision Oncology News - 2 weeks (NewA1)	durvalumab Sensitive: A1 - Approval Precision Oncology News - 2 weeks - (New A2)
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria Lancet Oncol - 2 weeks (NewC2)	atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria Lancet Oncol - 2 weeks - (New C3)
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK1 inhibitor Sensitive: C3 – Early Trials Thorac Cancer - 2 weeks (NewC3)	ALK1 inhibitor Sensitive: C3 – Early Trials Thorac Cancer - 2 weeks - (New C3)
BRAF V600E + BRAF K601_W604del BRAF V600E + BRAF K601_W604del	Non Small Cell Lung Cancer NSCLC	BRAF V600E + BRAF K601_W604del BRAF V600E + BRAF K601_W604del	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: C4 – Case Studies Cancer Genet - 2 weeks (NewC4)	trametinib + dabrafenib Sensitive: C4 – Case Studies Cancer Genet - 2 weeks - (New C4)
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	selinexor + MRTX1257 Sensitive: D – Preclinical Cancer Res Commun - 2 weeks (NewD)	selinexor + MRTX1257 Sensitive: D – Preclinical Cancer Res Commun - 2 weeks - (New D)
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	sotorasib + selinexor Sensitive: D – Preclinical Cancer Res Commun - 2 weeks (NewD)	sotorasib + selinexor Sensitive: D – Preclinical Cancer Res Commun - 2 weeks - (New D)
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval ecancer - 3 weeks (NewA1)	osimertinib Sensitive: A1 - Approval ecancer - 3 weeks - (New C3)
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria Clin Drug Investig - 3 weeks (NewC2)	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria Clin Drug Investig - 3 weeks - (New C3)
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	aumolertinib Sensitive: C2 – Inclusion Criteria J Exp Clin Cancer Res - 3 weeks (NewC2)	aumolertinib Sensitive: C2 – Inclusion Criteria J Exp Clin Cancer Res - 3 weeks - (New D)
PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 underexpression PD-L1 underexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Clin Exp Immunol - 3 weeks (NewC3)	Immunotherapy Sensitive: C3 – Early Trials Clin Exp Immunol - 3 weeks - (New C3)
MET mutation MET mutation	Non Small Cell Lung Cancer NSCLC	MET mutation MET mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials Thorac Cancer - 3 weeks (NewC3)	Immunotherapy Resistant: C3 – Early Trials Thorac Cancer - 3 weeks - (New C3)
SMARCA4 deletion SMARCA4 deletion	Non Small Cell Lung Cancer NSCLC	SMARCA4 deletion SMARCA4 deletion	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Resistant: C3 – Early Trials Lung Cancer - 3 weeks (NewC3)	PD-L1 inhibitor Resistant: C3 – Early Trials Lung Cancer - 3 weeks - (New C3)
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR inhibitor Sensitive: C3 – Early Trials PLoS One - 3 weeks (NewC3)	EGFR inhibitor Sensitive: C3 – Early Trials PLoS One - 3 weeks - (New C3)
MYC overexpression MYC overexpression	Non Small Cell Lung Cancer NSCLC	MYC overexpression MYC overexpression	Non Small Cell Lung Cancer NSCLC	ROS1 inhibitor Resistant: D – Preclinical Mol Cancer Res - 3 weeks (NewD)	ROS1 inhibitor Resistant: D – Preclinical Mol Cancer Res - 3 weeks - (New D)
ROR1 positive ROR1 positive	Non Small Cell Lung Cancer NSCLC	ROR1 positive ROR1 positive	Non Small Cell Lung Cancer NSCLC	LYL797 Sensitive: D – Preclinical ASGCT 2022 - 3 weeks (NewD)	LYL797 Sensitive: D – Preclinical ASGCT 2022 - 3 weeks - (New D)
EGFR mutation+ IDH1 R132H EGFR mutation+ IDH1 R132H	Non Small Cell Lung Cancer NSCLC	EGFR mutation+ IDH1 R132H EGFR mutation+ IDH1 R132H	Non Small Cell Lung Cancer NSCLC	erlotinib + AGI-5198 Sensitive: D – Preclinical Cancer Med - 3 weeks (NewD)	erlotinib + AGI-5198 Sensitive: D – Preclinical Cancer Med - 3 weeks - (New D)
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval	osimertinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	ramucirumab Sensitive: A1 - Approval	ramucirumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval	brigatinib Sensitive: A1 - Approval
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	sotorasib Sensitive: A1 - Approval	sotorasib Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval	osimertinib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval	brigatinib Sensitive: A1 - Approval
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	tepotinib Sensitive: A1 - Approval	tepotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A1 - Approval	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: A1 - Approval	lazertinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	capmatinib Sensitive: A1 - Approval	capmatinib Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval	cemiplimab Sensitive: A1 - Approval
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: A1 - Approval	pralsetinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	cisplatin + pemetrexed Sensitive: A1 - Approval	cisplatin + pemetrexed Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval	cisplatin Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval	crizotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval	crizotinib Sensitive: A1 - Approval
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	selpercatinib Sensitive: A1 - Approval	selpercatinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	mobocertinib Sensitive: A1 - Approval	mobocertinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: A1 - Approval	tislelizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	DP Sensitive: A1 - Approval	DP Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ensartinib Sensitive: A1 - Approval	ensartinib Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	savolitinib Sensitive: A1 - Approval	savolitinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: A1 - Approval	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pemetrexed Sensitive: A1 - Approval	pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	nintedanib Sensitive: A1 - Approval	nintedanib Sensitive: A1 - Approval
EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval	necitumumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval	trametinib + dabrafenib Sensitive: A1 - Approval
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw Sensitive: A1 - Approval	amivantamab-vmjw Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	docetaxel Sensitive: A1 - Approval	docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A1 - Approval	ceritinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	aumolertinib Sensitive: A1 - Approval	aumolertinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + erlotinib Sensitive: A1 - Approval	bevacizumab + erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: A1 - Approval	sintilimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval	erlotinib + ramucirumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval	erlotinib + ramucirumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Non Small Cell Lung Cancer NSCLC	BRAF V600 BRAF V600	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval	trametinib + dabrafenib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	tislelizumab Sensitive: A1 - Approval	tislelizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval	cemiplimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	sintilimab Sensitive: A1 - Approval	sintilimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
EGFR mutation + ALK negative + TMB-H EGFR mutation + ALK negative + TMB-H	Non Small Cell Lung Cancer NSCLC	EGFR mutation + ALK negative + TMB-H EGFR mutation + ALK negative + TMB-H	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	dabrafenib Sensitive: A2 - Guideline	dabrafenib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A2 - Guideline	ceritinib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A2 - Guideline	alectinib Sensitive: A2 - Guideline
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A2 - Guideline	lorlatinib Sensitive: A2 - Guideline
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A2 - Guideline	osimertinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Sensitive: A2 - Guideline	ALK inhibitor Sensitive: A2 - Guideline

Non Small Cell Lung Cancer

Associations(2605)

Associations
(2605)